AlloCure Secures $25,000,000 Series B Funding Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=3231c331-a1d8-4fd5-8427-eacd54997726&Preview=1 -
Date
4/2/2012 -
Company Name
AlloCure -
Mailing Address
25 Corporate Dr. Burlington, MA 01803 -
Company Description
Allocure is poised to be the first company to develop viable cell therapies for the effective treatment of many serious and debilitating medical conditions. AlloCure’s cell therapies represent a novel and proprietary class of biological therapeutics that will change the way a number of serious illnesses are treated. AlloCure’s most advanced therapies target acute kidney injury (AKI), kidney transplantation and multi organ failure. AlloCure’s Phase I Clinical Trial for AKI will begin in July of 2008. -
Website
http://www.allocure.com -
Transaction Type
M&A -
Transaction Amount
$25,000,000 -
Transaction Round
-
Proceeds Purposes
-
M&A Terms
Undisclosed -
Venture Investor
SV Life Sciences -
Venture Investor
Novo A/S
